Walk into the right Whole Foods early this year and you might find bacon that never came from a pig—it's grown from mycelium in upstate New York. Peer into the freezer at a handful of pizzerias, and there's mozzarella containing precision-fermented casein, molecularly identical to dairy protein but manufactured in steel fermentation tanks. Flip over a Crocs box, and the packaging ink? Derived from algae.
After a decade of pilot facilities, regulatory limbo, and venture capital patience wearing thin, synthetic biology companies are actually shipping products. Not next year. Not "pending approval." Now.
The inflection point everyone kept promising? It might finally be here.
Dairy Without Cows
Perfect Day's been at this longer than most. The company secured FDA clearance—a "no questions" letter, in regulatory parlance—for its animal-free whey protein back in March 2020. ProFerm is already flowing into ice cream, cream cheese, baked goods, and protein shakes through a roster of B2B partners. The company doesn't trumpet consumer brand names the way it used to, but multiple products are in market.
New Culture is pushing further. In January 2025, the startup filed paperwork with California's Department of Food and Agriculture for its precision-fermented casein mozzarella. Less than two months later, it reported $5 million in pre-launch orders from pizzerias—a signal that foodservice buyers see this as something more than a science experiment. Pizza operators don't commit cash to novelties.
Onego Bio, meanwhile, snagged FDA clearance for its Bioalbumen ovalbumin in September 2025. The Finnish company picked up a 25.9-acre campus in Wisconsin and is gearing up for U.S. production. The EVERY Company has been selling ovalbumin and egg-white ingredients commercially since around 2021 or 2022, offering a template for newcomers trying to navigate the B2B gauntlet.
Then there's the β-lactoglobulin crowd. Remilk landed FDA GRAS status for its version—brewed in Komagataella phaffii yeast—back in February 2023. Imagindairy self-affirmed GRAS in August of that year. Vivici, a joint venture between DSM-firmenich and New Zealand dairy giant Fonterra, began cranking out commercial volumes in the U.S. as of March 2025.
The pattern's consistent: regulatory clearances secured, manufacturing scaled, distribution agreements inked. The dominos are falling.
Ingredients That Rebuild the Pantry
Sweeteners were among the first to break through. Avansya—a joint venture between Cargill and DSM-firmenich—has EverSweet in commercial circulation. The fermentation-derived stevia blend (Reb M and Reb D) received positive opinions from European regulators in 2024, with EU approval confirmed by Cargill's EMEA division by 2025. A lifecycle assessment published last April positioned it as a sustainability play as much as a taste upgrade. And unlike some synbio hopefuls, EverSweet is already penciling out economically.
Fats are trickier. Plant-based meats have struggled with mouthfeel and aroma—technical gaps that even well-funded startups couldn't engineer around with pea protein and coconut oil alone. Nourish Ingredients thinks it has an answer. The Australian company struck a deal with CABIO Biotech, announced April 9, 2025, to scale production of its "designer fats" platform, including Tastilux. A European commercial hub in Leiden is set to go live this year. These fats aim to mimic the sensory profile of animal fats in plant-based burgers and sausages.
Color is the other frontier. Consumers want clean labels; regulators want safety data; brands want consistency. Fermentation offers a path. Phytolon and Ginkgo Bioworks hit a milestone on April 30, 2025, nearly tripling manufacturing efficiency for Phytolon's natural food colors. Michroma formed a partnership with South Korean biotech giant CJ CheilJedang last September to scale production of its red colorant. Denmark's Chromologics raised €7 million in November 2025 to push its Natu.Red toward commercial launch.
Impossible Foods blazed this trail years ago—its soy leghemoglobin, the "heme" that makes the Impossible Burger bleed, received FDA approval as a color additive back in 2019. It's been in grocery stores ever since. Regulators have precedent now.
Mycelium Goes Mainstream
MyForest Foods rolled out mycelium bacon and pulled pork across Whole Foods nationwide in October 2025. The launch followed a funding round announced last April to juice up production capacity. For a category that's mostly stayed niche, landing a national Whole Foods distribution deal represents something of a step change.
Nature's Fynd launched its Fy Yogurt—built on a fungi protein platform—at Whole Foods back in January 2024. By April 2025, the company had expanded into Fy Bites and a culinary base for foodservice, showcased at the National Restaurant Association Show. The protein comes from a microorganism originally discovered in Yellowstone's geothermal springs, a reminder that synbio often begins in extreme environments with unusual organisms doing improbable chemistry.
Meati Foods expanded into breakfast patties in January 2025, though the company hit turbulence by March with layoffs and uncertainty around facility closures. Distribution status remains murky.
Materials and Chemicals Escape the Lab
LanzaTech's been at the industrial-waste-to-ethanol game for years, but the products are starting to show up in unexpected places. The company's CarbonSmart ethanol—derived from industrial off-gases—is being spun into polyester for fashion. Running shoe brand On used it for CleanCloud. Zara featured it in a collection. In fragrance, Coty and Gucci incorporated CarbonSmart ethanol into the "Where My Heart Beats" scent, released in 2023. LanzaTech's also announced plans to expand into CO₂-derived nutritional protein, with pre-commercial facilities targeted for this year.
Qore, a Cargill and HELM joint venture, flipped the switch on commercial production at its bio-based 1,4-butanediol (bio-BDO) plant in Eddyville, Iowa, in July 2025. The facility has a nameplate capacity of 66,000 tonnes per year—industrial volume, not pilot scale. Offtake agreements with BASF and LYCRA provide demand certainty. Bio-BDO is a building block for plastics, fibers, and elastomers. Unglamorous, perhaps, but essential.
Solugen secured a $213.6 million conditional loan guarantee from the Department of Energy in June 2024 to build its Bioforge Marshall facility in Minnesota. The plant broke ground last April, with production slated for fall 2025. Solugen's chemo-enzymatic platform produces organic acids and chemicals for water treatment, construction, agriculture, and energy—high-volume, low-glamor markets where margins live or die on pennies per kilogram.
In textiles, Spiber's Brewed Protein fiber showed up in The North Face and other brands in September 2023. The Japanese startup showcased over 100 new fabrics at Milano Unica in early February 2025. Then came a mobility debut: the Toyota Land Cruiser Prado "NEWSCAPE" special edition features seats using Brewed Protein fiber, with commercial release planned for this spring.
AMSilk extended its manufacturing partnership with Evonik last September, establishing a dedicated production line in Slovakia for premium fashion and automotive interiors. The company's spider-silk-like proteins debuted in Balenciaga's Spring 2026 collection on January 21. Modern Synthesis, working with bacterial nanocellulose textiles, raised $5.5 million in February 2025 to scale its microbial textile platform.
Living Ink's Algae Black pigment and Algae Ink are in commercial circulation. Crocs debuted CMYK-printed packaging using Algae Ink last August—a packaging application that sidesteps some of the regulatory complexity that comes with food-contact materials.
What It Actually Took
Regulatory clearance came first. FDA "no questions" letters, GRAS self-affirmations, EU novel food approvals—these provided legal cover to ship. But clearance alone guaranteed nothing. Plenty of FDA-approved ingredients sit on shelves gathering dust because nobody can make them cheaply enough or reliably enough to matter.
Scale-up partnerships followed. Nourish with CABIO. Michroma with CJ CheilJedang. AMSilk with Evonik. Phytolon with Ginkgo Bioworks. These tie-ups brought fermentation expertise, contract manufacturing capacity, and capital for dedicated production lines. Synbio startups discovered what pharmaceutical biotech learned decades ago: you can't do it alone.
Distribution deals closed the loop. Perfect Day's B2B model. New Culture's $5 million in pre-orders. MyForest Foods landing Whole Foods nationwide. Qore's offtake agreements with BASF and LYCRA. These are proof points of commercial traction—actual purchase orders, not press release vaporware.
Some setbacks linger, of course. Bolt Threads confirmed it was pulling the plug on Mylo, its mycelium leather, in early 2023. Cultivated meat from UPSIDE Foods and GOOD Meat—approved by USDA in June 2023 and served at a handful of restaurants by mid-2023—remains vanishingly scarce. Meati's future is uncertain following layoffs.
The broader infrastructure is maturing, though. Novonesis, formed from the January 2024 merger of Novozymes and Chr. Hansen, released its annual report on February 25, 2026, reporting revenue growth across its Food & Health and Planetary Health biosolutions segments. The company launched numerous yeast and enzyme products in 2024 and 2025 for ethanol production and agriculture. Established players are betting on the category now, not just venture-backed startups.
Solar Foods' Factory 01 in Vantaa, Finland, began operations in 2024 and hit full design capacity by October 2025. The company's Solein protein—produced via air fermentation—launched in New York last November through a restaurant partnership, following earlier approvals in Singapore. Calysta's FeedKind single-cell protein is in commercial production at its Chongqing facility, with production updates as recent as late February.
Flavor and fragrance companies are shipping, too. BASF's Isobionics unit launched fermentation-based Natural β-Sinensal 20 and Natural α-Humulene 90 on March 24, 2025. Sensegen (part of Blue California) formed a strategic collaboration with Takasago in January 2024, advancing its biotech-based taste and smell portfolio. Debut announced a plant cell biotechnology platform for fragrance molecules, including orris, last July.
The Economics Are Starting to Work
The question in 2026 isn't whether synthetic biology can produce molecules at scale—it's whether these products can compete on cost, performance, and reliability with the incumbents they're designed to replace. For some applications, the answer is already yes.
EverSweet is in commercial use because it works and the economics close. Qore's bio-BDO has committed offtakers because BASF and LYCRA see value in locking in supply. Living Ink's algae pigments landed Crocs packaging because the business case penciled out.
Others remain premium-priced, banking on sustainability-conscious brands willing to absorb higher costs—at least initially. AMSilk in Balenciaga. Spiber in Toyota interiors. Nature's Fynd yogurt at Whole Foods. The commercial logic is different here: early adopter brands subsidize the learning curve, and scale eventually drives cost down. Maybe.
What's clear is that the bottleneck has shifted. It's no longer "Can we make this?" It's "Can we make enough of it, reliably, at a price point that works?" The companies shipping products in 2026 have crossed that threshold, or are close enough to bet capital on it.
The supply chain is real. Fermentation capacity is expanding. Regulatory pathways are established. Offtake agreements are signed.
The shelves are stocked. The harder part—getting customers to keep buying—is just beginning.
